Expert Review of Gastroenterology & Hepatology最新文献_第2页

Biliary drainage in perihilar cholangiocarcinoma: historical rationale and the evolving case for selective use. 肝门周围胆管癌的胆道引流：选择性使用的历史依据和不断发展的案例。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-09-01 Epub Date: 2026-09-14 DOI: 10.1080/17474124.2026.2729325

Julien A Luyten, Brendan J Clark, Judith de Vos-Geelen, Frank G Schaap, Otto van Delden, Jan-Werner Poley, Thomas van Gulik, Bas Groot Koerkamp, Ulf P Neumann, Maxime J L Dewulf, Steven W M Olde Damink

{"title":"Biliary drainage in perihilar cholangiocarcinoma: historical rationale and the evolving case for selective use.","authors":"Julien A Luyten, Brendan J Clark, Judith de Vos-Geelen, Frank G Schaap, Otto van Delden, Jan-Werner Poley, Thomas van Gulik, Bas Groot Koerkamp, Ulf P Neumann, Maxime J L Dewulf, Steven W M Olde Damink","doi":"10.1080/17474124.2026.2729325","DOIUrl":"10.1080/17474124.2026.2729325","url":null,"abstract":"Introduction: Cholestasis prevents optimal treatment of perihilar cholangiocarcinoma (pCCA). To counteract this, biliary drainage (BD) has long been regarded as mandatory prior to any treatment. However, increasing evidence has highlighted the risks associated with BD, notably cholangitis, indicating that while often necessary, drainage requires careful clinical judgment.Areas covered: This narrative literature review outlines the historical development of BD and its rationales, including the restoration of liver function, a prerequisite for liver hypertrophy-inducing procedures, and improvement of performance status. The review also addresses its drawbacks, particularly the risk of cholangitis due to bacterial colonization of the biliary tree and summarizes the evidence shaping contemporary clinical practice.Expert opinion: Once regarded as mandatory, BD can no longer be justified as a routine intervention for every pCCA patient, given the associated risks. Undrained partial hepatectomy should be considered in patients with moderate bilirubin levels, adequate future liver remnant volume, absence of cholangitis, normal performance status, and preserved liver and renal function. Still, this applies to only a minority of patients. Similarly, systemic therapy may be feasible without BD in highly selected patients. Future research should focus on defining selection criteria, investigating new biomarkers of cholestasis, and refining drainage techniques to minimize complications of BD.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"765-778"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IPMN beyond the cyst: toward a broader framework of pancreatic and systemic cancer susceptibility. 囊肿外的IPMN：朝着胰腺和全身癌症易感性的更广泛框架发展。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-09-01 Epub Date: 2026-09-21 DOI: 10.1080/17474124.2026.2737415

Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura

{"title":"IPMN beyond the cyst: toward a broader framework of pancreatic and systemic cancer susceptibility.","authors":"Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura","doi":"10.1080/17474124.2026.2737415","DOIUrl":"10.1080/17474124.2026.2737415","url":null,"abstract":"Introduction: Intraductal papillary mucinous neoplasms (IPMNs) are established precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Although current guidelines primarily focus on lesion morphology, emerging evidence suggests that IPMN may also be associated with broader pancreatic and extrapancreatic cancer risk.Areas covered: This review examines pancreatic field cancerization, including concomitant and metachronous PDACs that may arise independently of the index IPMN. We evaluate reported associations between IPMN and extrapancreatic malignancies, including colorectal, gastric, and breast cancers, while considering surveillance bias, age, shared environmental factors, and hereditary susceptibility. We further discuss germline pathogenic variants, including BRCA1/2, PALB2, and ATM, and identify clinical features that may support risk-adapted genetic assessment. Emerging approaches, including liquid biopsy, radiomics, artificial intelligence, and multi-omics, are evaluated as potential tools for individualized surveillance.Expert opinion: IPMN may represent more than an isolated pancreatic precursor lesion and may identify selected patients with broader cancer susceptibility. However, current evidence is predominantly observational and does not establish causality. Future management should complement established guidelines with risk-adapted, patient-centered assessment. Emerging technologies may refine individualized risk stratification but require prospective validation before routine clinical implementation.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"795-805"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Food-based enteral formulas in pediatric clinical practice: an expert opinion. 儿童临床实践中基于食物的肠内配方：专家意见。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-09-01 Epub Date: 2026-09-14 DOI: 10.1080/17474124.2026.2726787

Graeme O'Connor, Antonella Diamanti, Chiara Maria Trovato, Claudio Romano, Gerard J Minor, Guy Letellier, Koen Huysentruyt, Lisa M Epp, Randi Tobberup, Sarah Durnan, Valeria Dipasquale, Valerie Marchand, Frederic Gottrand

{"title":"Food-based enteral formulas in pediatric clinical practice: an expert opinion.","authors":"Graeme O'Connor, Antonella Diamanti, Chiara Maria Trovato, Claudio Romano, Gerard J Minor, Guy Letellier, Koen Huysentruyt, Lisa M Epp, Randi Tobberup, Sarah Durnan, Valeria Dipasquale, Valerie Marchand, Frederic Gottrand","doi":"10.1080/17474124.2026.2726787","DOIUrl":"10.1080/17474124.2026.2726787","url":null,"abstract":"Introduction: Standard enteral formulas are widely used in pediatric practice but may be associated with gastrointestinal intolerance, limited food diversity, and caregiver dissatisfaction. Growing interest in whole-food feeding has led to increased use of blenderized tube feeds and food-based enteral formulas (FBEFs), although definitions and implementation strategies remain heterogeneous.Areas covered: This expert opinion review summarizes evidence and practice-based insights from an international, multidisciplinary panel of physicians and dieticians on the use of FBEF in pediatric clinical practice. The article was informed by a narrative literature review and a structured expert discussion. Key domains addressed: definition of FBEF, physiological and psychosocial benefits, clinical indications, administration route, transition to adult care; in comparison with homemade blenderized tube feeding.Expert opinion: The current evidence, together with real-life experience in clinical practice, suggests that FBEFs are well tolerated and may improve reflux, vomiting, bowel habits, and, caregiver-reported satisfaction. FBEFs offer standardized nutritional composition, food safety, shelf stability, and a lower preparation burden, while still aligning with families' preferences for food-derived ingredients. In our opinion, FBEFs represent a viable option for children requiring long-term enteral feeding, particularly those with intolerance to standard formulas, provided that product selection, monitoring, and caregiver education are individualized.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"779-793"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rome V criteria for pediatric disorders of gut-brain interaction: key updates and clinical implications. 小儿肠脑相互作用疾病的罗马标准：关键更新和临床意义。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-08-01 Epub Date: 2026-08-03 DOI: 10.1080/17474124.2026.2712930

Shaman Rajindrajith, Niranga Devanarayana, Wathsala Hathagoda, Marc Benninga

{"title":"Rome V criteria for pediatric disorders of gut-brain interaction: key updates and clinical implications.","authors":"Shaman Rajindrajith, Niranga Devanarayana, Wathsala Hathagoda, Marc Benninga","doi":"10.1080/17474124.2026.2712930","DOIUrl":"10.1080/17474124.2026.2712930","url":null,"abstract":"Introduction: The Rome criteria have provided the acclaimed global standard for diagnosing pediatric functional gastrointestinal disorders. With the release of Rome criteria V in 2026, the field has undergone a major transformation. The notable changes are the replacement of the term functional gastrointestinal disorders with disorders of gut-brain interaction (DGBIs) and shifting from age-based subdivisions to an anatomical and symptom cluster framework.Area covered: We reviewed pediatric Rome V documents and available evidence to cover both upper and lower gastrointestinal disorders of gut-brain interaction (DGBI). The new diagnostic entities such as reflux hypersensitivity, reflux negative esophageal pain disorder, supragastric belching, functional pediatric feeding disorders, centrally mediated abdominal pain syndrome, biliary pain syndrome, proctalgia fugax, functional diarrhea, functional bloating, and infant distress syndrome were discussed in detail.Expert opinion: Rome V provides clinicians with a more precise diagnostic framework. However, many new entities remain descriptive, highlighting the urgent need for epidemiological studies, mechanistic research, and biomarker discovery. Large multicenter trials, in DGBI should be conducted using physiological studies, microbiome analysis, and psychosocial profiles to generate robust evidence on pathophysiology, and management strategies. Ultimately, Rome V should be seen as a launchpad for discovery-transforming descriptive categories into mechanically defined, therapeutically actionable disorders that improve outcomes for children worldwide.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"721-732"},"PeriodicalIF":3.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in the therapeutic management of acid-related gastrointestinal diseases. 酸相关胃肠道疾病治疗管理的最新进展。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-08-01 Epub Date: 2026-07-21 DOI: 10.1080/17474124.2026.2706854

Aitor Lanas-Gimeno, Angel Lanas

{"title":"Recent developments in the therapeutic management of acid-related gastrointestinal diseases.","authors":"Aitor Lanas-Gimeno, Angel Lanas","doi":"10.1080/17474124.2026.2706854","DOIUrl":"10.1080/17474124.2026.2706854","url":null,"abstract":"Introduction: Acid-related gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), remain major global health burdens despite decades of proton pump inhibitor (PPI)-based therapy. Persistent symptoms, nocturnal acid breakthrough, refractory disease, antibiotic resistance in Helicobacter pylori infection, and interindividual pharmacogenomic variability continue to limit current management strategies.Areas covered: This review summarizes therapeutic advances in acid-related diseases, focusing on articles published between 2020 and 2025 and on potassium-competitive acid blockers (P-CABs), mucosal protective agents, adjunctive pharmacotherapies, endoscopic anti-reflux interventions, and precision medicine studies. Literature from randomized controlled trials, meta-analyses, international guidelines, and observational studies was reviewed to evaluate the efficacy, safety, and clinical positioning of emerging therapies in GERD, PUD, and H. pylori eradication. The search was conducted in PubMed.Expert opinion: P-CABs, particularly vonoprazan, represent the most important advance in acid suppression in recent decades, offering faster, more potent, and more predictable acid inhibition than PPIs. Precision approaches integrating GERD phenotyping, pharmacogenomics, and antibiotic susceptibility testing are shifting management toward individualized care. However, long-term safety data, cost-effectiveness analyses, and robust comparative trials remain limited. Future progress will likely depend on combining phenotype-directed pharmacologic, endoscopic, and microbiome-informed strategies supported by artificial intelligence-driven diagnostics and treatment selection.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"683-700"},"PeriodicalIF":3.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatitis C: innovations in therapeutic interventions and elimination strategies. 丙型肝炎：治疗干预和消除策略的创新。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-08-01 Epub Date: 2026-08-16 DOI: 10.1080/17474124.2026.2716819

Conor Moran, Marianne Martinello, Gregory J Dore

{"title":"Hepatitis C: innovations in therapeutic interventions and elimination strategies.","authors":"Conor Moran, Marianne Martinello, Gregory J Dore","doi":"10.1080/17474124.2026.2716819","DOIUrl":"10.1080/17474124.2026.2716819","url":null,"abstract":"Introduction: Hepatitis C virus (HCV) affects approximately 47 million people worldwide and remains a major cause of chronic liver disease and liver-related mortality. Although direct-acting antiviral (DAA) therapy has transformed HCV into a highly curable infection, persistent gaps in diagnosis, linkage to care, harm reduction coverage, and health-system capacity impede progress toward World Health Organization (WHO) 2030 elimination targets.Areas covered: This review summarizes advances in HCV therapeutics, including pangenotypic DAA regimens, shortened treatment strategies, and emerging antiviral agents, and examines treatment in special populations, including decompensated cirrhosis, acute HCV, transplant recipients, children, people who inject drugs, and pregnant women. It also explores diagnostic innovations and implementation strategies to accelerate elimination, including point-of-care HCV RNA testing, reflex testing, decentralized care, and microelimination frameworks. PubMed, Embase, and Google Scholar were searched from inception to March 2026.Expert opinion: Modern DAA regimens cure over 95% across most populations, but eliminating HCV as a public health threat will require prioritizing underserved populations, simplified diagnostic pathways, equitable access to treatment and retreatment, and investment in harm reduction. Antenatal DAA therapy, ultra-short regimens, and long-acting antivirals represent the next frontier, though elimination will depend on implementation science as much as pharmacological innovation.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"701-719"},"PeriodicalIF":3.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heller myotomy for esophageal achalasia: risk factors for reintervention - a narrative review. 海勒肌切开术治疗食道贲门失弛缓症：再干预的危险因素-一篇叙述性综述。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-08-01 Epub Date: 2026-07-27 DOI: 10.1080/17474124.2026.2706855

Arianna Vittori, Renato Salvador, Luca Provenzano, Giovanni Zaninotto

{"title":"Heller myotomy for esophageal achalasia: risk factors for reintervention - a narrative review.","authors":"Arianna Vittori, Renato Salvador, Luca Provenzano, Giovanni Zaninotto","doi":"10.1080/17474124.2026.2706855","DOIUrl":"10.1080/17474124.2026.2706855","url":null,"abstract":"Introduction: Heller myotomy (HM) is an effective and durable treatment for esophageal achalasia. However, some patients experience persistent or recurrent symptoms that require reintervention. Heterogeneous definitions of failure after HM limit comparability across studies and complicate clinical decision-making.Areas covered: This narrative review examines definitions and incidence of failure after HM, as well as risk factors for reintervention. Failure is influenced by disease severity, esophageal morphology, manometric type, prior endoscopic therapy, surgical technique, and center experience. Reported failure rates vary because of inconsistent definitions, follow-up durations, and patient selection. Symptom-based tools, such as the Eckardt Score, remain central but have limitations, underscoring the need for validated measures. Sigmoid esophagus and type I-III achalasia increase the risk of failure, whereas prior endoscopic therapy does not predict adverse outcomes in high-volume centers. Compared with endoscopic myotomy, HM-fundoplication may reduce postoperative reflux.Expert opinion: Achalasia is irreversible, and treatment is palliative. Laparoscopic HM remains the gold standard, though failures occur, often due to incomplete myotomy or advanced disease. Early intervention, accurate diagnosis, and meticulous surgical technique are essential. Future research should prioritize standardized definitions of failure, type-specific outcome reporting, and long-term follow-up to enhance comparability and guide management.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"733-746"},"PeriodicalIF":3.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal manifestations of common variable immunodeficiency: what a gastroenterologist needs to be aware of. 常见可变免疫缺陷的胃肠道表现：胃肠病学家需要注意的问题。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-08-01 Epub Date: 2026-08-17 DOI: 10.1080/17474124.2026.2716136

Drew M Levy, Matthew Meriwether, Mary R Schwartz, Shrinivas Bishu, Eamonn M M Quigley

{"title":"Gastrointestinal manifestations of common variable immunodeficiency: what a gastroenterologist needs to be aware of.","authors":"Drew M Levy, Matthew Meriwether, Mary R Schwartz, Shrinivas Bishu, Eamonn M M Quigley","doi":"10.1080/17474124.2026.2716136","DOIUrl":"10.1080/17474124.2026.2716136","url":null,"abstract":"Introduction: Common variable immunodeficiency disorder (CVID) is the most common symptomatic primary immunodeficiency disorder and, given its predilection to affect the gastrointestinal (GI) tract, will be encountered in the practice of a general gastroenterologist, as well as those with more focused interests.Areas covered: Gastrointestinal and hepatic manifestations of CVID - their clinical presentation, endoscopic, imaging and pathological features. Also reviewed, in detail, diagnostic and therapeutic issues that the clinician may be confronted with in dealing with these disorders.Expert opinion: Among the protean GI manifestations of CVID a predisposition to enteric infections, chronic gastritis, enteropathy and a form of inflammatory bowel disease feature prominently. Each poses diagnostic and therapeutic challenges; differentiation from celiac disease, Crohn's disease and ulcerative colitis may be challenging, emphasizing the need for awareness of the possibility of CVID when clinical features are atypical. The liver may also be involved, and the gastroenterologist needs to be especially aware of the higher prevalence of gastrointestinal cancer in this patient population.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"673-682"},"PeriodicalIF":3.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing nutritional care across the continuum from intensive care to recovery: an expert opinion review. 优化营养护理在整个连续体从重症监护到恢复：专家意见审查。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-07-22 DOI: 10.1080/17474124.2026.2703204

Arthur R H van Zanten, Pavel Kohout, Elisabeth De Waele, Heather Keller

{"title":"Optimizing nutritional care across the continuum from intensive care to recovery: an expert opinion review.","authors":"Arthur R H van Zanten, Pavel Kohout, Elisabeth De Waele, Heather Keller","doi":"10.1080/17474124.2026.2703204","DOIUrl":"10.1080/17474124.2026.2703204","url":null,"abstract":"Introduction: Survivorship after critical illness is frequently complicated by muscle wasting and gastrointestinal (GI) dysfunction, driving prolonged functional impairment. Nutrition is a modifiable determinant across the intensive care unit (ICU)-to-home continuum, yet delivery is commonly limited by feeding intolerance and fragmented transitions of care.Areas covered: This expert opinion review synthesizes evidence identified via a narrative search of MEDLINE/PubMed and key guideline/reference screening, focusing on GI dysfunction as a barrier to enteral nutrition (EN) in the ICU, phase-adapted energy and protein provision, and strategies to restore intake during ward recovery and after discharge, including high-energy, protein-dense oral nutritional supplements (ONS).Expert opinion: Nutrition should be delivered as a structured pathway rather than a single ICU intervention. Early EN with proactive, symptom-targeted management of GI dysfunction, coupled with stepwise protein escalation aligned to metabolic phase and organ function, may help reduce avoidable deficits. The early post-ICU period is an anabolic 'window of opportunity' that warrants intake monitoring, deliberate tapering of tube feeds only once oral intake is reliable, and routine post-discharge ONS for patients at nutritional risk. Research should prioritize pragmatic trials of phase-specific targets and transition-of-care models.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-17"},"PeriodicalIF":3.3,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions. 炎症性肠病的FAPI PET：一个关于成纤维细胞活性的新窗口，有未解的临床问题。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-07-01 Epub Date: 2026-06-11 DOI: 10.1080/17474124.2026.2686248

Luca Filippi, Esra Arslan, Halil Komek, Laura Evangelista

{"title":"FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.","authors":"Luca Filippi, Esra Arslan, Halil Komek, Laura Evangelista","doi":"10.1080/17474124.2026.2686248","DOIUrl":"10.1080/17474124.2026.2686248","url":null,"abstract":"Accurate assessment of inflammatory activity in inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) remains a major clinical challenge. Positron emission tomography (PET) with fibroblast activation protein inhibitors (FAPI) has recently attracted considerable interest for its ability to visualize fibroblast-associated tissue remodeling and stromal activation in inflammatory conditions. In the study under evaluation, Debus et al. report a retrospective pilot study of [68Ga]Ga-FAPI-46 PET/CT for noninvasive characterization and activity assessment of CD and UC. Forty-three histologically confirmed IBD patients (20 CD and 23 UC) and 43 matched controls underwent dynamic abdominal (60 min) and whole-body [68Ga]Ga-FAPI-46 PET/CT to quantify FAPI uptake, kinetics, and lesion burden, with imaging findings compared with colonoscopy. They found significantly higher FAPI uptake in both FAPI-positive lesions and in many 'healthy-appearing' gut segments of IBD patients versus controls; uptake was greater in active versus inactive disease, and lesions displayed two characteristic kinetic patterns that can further stratify inflammatory disease. The study is an important, hypothesis-generating contribution that supports the feasibility and biological plausibility of FAPI PET for IBD, but its retrospective design, modest sample size, limited histologic lesion-level correlation and control selection temper conclusions about diagnostic performance and clinical utility.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"621-625"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0